Department of ENT and Head and Neck Surgery, Indraprastha Apollo Hospitals, New Delhi, IndiaFulltext PDF
Mucormycosis is almost always confined to the patients with altered host defenses and diabetes is considered as the strongest risk factor for it. COVID-19 had a great impact on the occurrence of mucormycosis, especially on diabetics. It has not only been seen in severe cases but also in mild and moderate cases of SARS-CoV-2 infections. In this case series 79 proven cases of COVID-19 associated rhino-orbital-cerebral mucormycosis are analyzed retrospectively between mid- April 2021 and mid-September 2021. Of these 79 cases, 27 cases had disease limited to sinuses (rhinomucormycosis), 43 had orbital involvement also (rhino-orbital mucormycosis) and 9 hadcerebral involvement as well (rhino-orbital-cerebral mucormycosis). After preliminary clinical and radiological diagnosis surgical management in the form of endoscopic sinus surgery, debridement and orbital exenteration (8) was performed. Medical management in the form of anti-fungal therapy (Amphotericin-B, Posaconazole and Isavuconazole) was also initiated. During this course of time total 14 mortality occurred and most of the patients were discharged after completion of Amphotericin-B therapy.
COVID-19; Rhino-orbital-cerebral mucormycosis; Diabetes; Debridement; Orbital exenteration
Rana N. COVID-19 Associated Rhino- Orbital-Cerebral Mucormycosis - An Institutional Series. Am J Otolaryngol Head Neck Surg. 2021; 4(11): 1166..